Abstract
As a consequence of its prevalence, early onset and chronicity, schizophrenia imposes clinical and economic impediments to healthcare practitioners. Among the armamentarium of agents available to treat the symptoms of this devastating illness, the atypical antipsychotics have received a great deal of attention. Although these agents have proven valuable, their use has often been limited as a result of high acquisition costs relative to the older conventional antipsychotics. This review examines the relevant literature concerning the pharmacoeconomics of clozapine, risperidone and olanzapine, and incorporates the findings into a discussion enveloping the general principles of pharmacoeconomics.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
